See more : KR Motors Co., Ltd. (000040.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Flexion Therapeutics, Inc. (FLXN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Flexion Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Eagle Point Institutional Incom (EIIA) Income Statement Analysis – Financial Results
- Landsea Homes Corporation (LSEA) Income Statement Analysis – Financial Results
- UMH Properties, Inc. (UMH) Income Statement Analysis – Financial Results
- Whirlpool Corporation (WHR) Income Statement Analysis – Financial Results
- Telefonaktiebolaget LM Ericsson (publ) (ERIC-A.ST) Income Statement Analysis – Financial Results
Flexion Therapeutics, Inc. (FLXN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: http://www.flexiontherapeutics.com
About Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 85.55M | 72.96M | 22.52M | 355.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 19.25M | 9.96M | 7.34M | 4.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 66.30M | 63.00M | 15.19M | 351.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 77.50% | 86.35% | 67.43% | 98.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 54.33M | 69.56M | 53.08M | 51.23M | 41.31M | 32.69M | 17.92M | 11.06M | 11.07M | 8.24M |
General & Administrative | 105.00M | 129.71M | 121.31M | 78.80M | 28.47M | 13.37M | 9.06M | 6.70M | 3.95M | 3.05M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 105.00M | 129.71M | 121.31M | 78.80M | 28.47M | 13.37M | 9.06M | 6.70M | 3.95M | 3.05M |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 159.32M | 199.27M | 174.39M | 130.03M | 69.78M | 46.06M | 26.99M | 17.77M | 15.01M | 11.29M |
Cost & Expenses | 178.57M | 209.23M | 181.73M | 130.04M | 69.78M | 46.06M | 26.99M | 17.77M | 15.01M | 11.29M |
Interest Income | 876.00K | 3.21M | 4.57M | 3.72M | 1.52M | 1.25M | 478.72K | 234.00K | 193.90K | 173.29K |
Interest Expense | 20.03M | 17.07M | 15.71M | 11.27M | 1.75M | 570.99K | 401.37K | 448.89K | 0.00 | 0.00 |
Depreciation & Amortization | 3.34M | 2.40M | 1.71M | 2.01M | 1.15M | 238.15K | 120.34K | 79.81K | 43.23K | 105.57K |
EBITDA | -89.84M | -130.31M | -152.23M | -124.21M | -69.00M | -45.51M | -26.79M | -17.66M | -14.94M | -11.34M |
EBITDA Ratio | -105.01% | -178.61% | -675.87% | -34,987.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -93.02M | -136.27M | -159.20M | -129.68M | -69.78M | -46.06M | -26.99M | -17.77M | -15.01M | -11.29M |
Operating Income Ratio | -108.73% | -186.78% | -706.81% | -36,529.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -20.19M | -13.50M | -10.46M | -7.80M | -2.11M | -252.38K | -326.39K | -421.52K | 30.02K | -159.38K |
Income Before Tax | -113.21M | -149.77M | -169.66M | -137.48M | -71.89M | -46.32M | -27.31M | -18.19M | -14.98M | -11.45M |
Income Before Tax Ratio | -132.33% | -205.29% | -753.24% | -38,727.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 495.00K | 3.56M | 5.26M | 3.47M | -366.48K | 318.62K | 74.98K | 27.37K | 30.02K | -159.38K |
Net Income | -113.71M | -149.77M | -169.66M | -137.48M | -71.89M | -46.32M | -27.31M | -18.19M | -14.98M | -11.45M |
Net Income Ratio | -132.91% | -205.29% | -753.24% | -38,727.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -2.66 | -3.93 | -4.49 | -4.16 | -2.84 | -2.15 | -1.97 | -1.23 | -2.04 | -1.18 |
EPS Diluted | -2.66 | -3.93 | -4.49 | -4.16 | -2.84 | -2.15 | -1.97 | -1.23 | -2.04 | -1.18 |
Weighted Avg Shares Out | 42.78M | 38.09M | 37.75M | 33.03M | 25.30M | 21.50M | 13.89M | 14.75M | 7.34M | 9.74M |
Weighted Avg Shares Out (Dil) | 42.78M | 38.09M | 37.75M | 33.03M | 25.30M | 21.50M | 13.89M | 14.75M | 7.34M | 9.74M |
$20.60 Million in Sales Expected for Flexion Therapeutics Inc (NASDAQ:FLXN) This Quarter
Flexion Therapeutics (NASDAQ:FLXN) Receives New Coverage from Analysts at Northland Securities
ERBA Diagnostics (OTCMKTS:ERBA) & Flexion Therapeutics (OTCMKTS:FLXN) Head to Head Analysis
Analysts Offer Insights on Healthcare Companies: Flexion Therapeutics (FLXN) and Dexcom (DXCM)
Northland Securities Initiates a Buy Rating on Flexion Therapeutics (FLXN)
Source: https://incomestatements.info
Category: Stock Reports